Naphtho-pyrans (including Hydrogenated) Patents (Class 549/389)
  • Patent number: 9249136
    Abstract: A naphthopyran compound represented by the formula (I): wherein: n1, n2, p, q is an integer comprised from 0 to 5 inclusive; m is an integer comprised from 0 to 4 inclusive; R1 and R2 represent a group selected from halogen, —Ra, —OH, —ORa, —SH, —SRa, —NH2, —NRaRa1, —NRbRc, —CO—Ra, and —CO2Ra1, wherein Ra, Ra1, Rb and Rc, are as defined in the description; R3 represents a group selected from halogen, —Ra, —OH, —ORa, —SH, —SRa, —NH2, and —NRaRa1; R4 represents a group selected from halogen, —Ra, —OH, —ORa, —SH, —SRa, —NH2, —NRaRa1, —CO—Ra, and —CO2Ra1; R5 represents a group selected from: halogen, —Ra, —OH, —ORa, —SH, —SRa, —NH2, and —NRaRa1, wherein Ra and Ra1 are as defined hereinbefore, or when q is equal to 2, then two R5 together represent further a group —O—(CH2)q1—O— wherein q1 represents an integer comprised from 1 to 3 inclusive.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: February 2, 2016
    Assignees: Essilor International (Compagnie Generale d'Optique), Alphamicron, Incorporated
    Inventors: Stuart Aiken, Jean-Paul Cano, Christopher David Gabbutt, Bernard Mark Heron, Tamas Kosa, Linli Su, Ludmila Sukhomlinova, Bahman Taheri
  • Patent number: 8969406
    Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: March 3, 2015
    Assignee: China Medical University
    Inventors: Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang, Da-Wei Chuang, Juan-Cheng Yang
  • Publication number: 20140330030
    Abstract: A method and associated system of treating a plant material consisting essentially of the plant cannabis in order to extract cannabinoids in liquid form from the plant material. The method includes heating the plant material; drying the plant material; grinding the dried plant material into a powder form; marinating the dried plant powder in a solvent for a predetermined time period to form a marinated mixture; shaking and heating the marinated mixture; filtering the mixture so that only a liquid part of the mixture remains; and evaporating from the liquid the solvent in order to provide the cannabinoid liquid extract.
    Type: Application
    Filed: February 18, 2014
    Publication date: November 6, 2014
    Inventor: Frederick R. Ferri
  • Publication number: 20140221470
    Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:
    Type: Application
    Filed: March 18, 2013
    Publication date: August 7, 2014
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: Yang-Chang WU, Kuo-Hsiung LEE, Fang-Rong CHANG, Da-Wei CHUANG, Juan-Cheng YANG
  • Publication number: 20140197361
    Abstract: A naphthopyran compound represented by the formula B1 and B2 are selected independently from the group consisting of a phenyl, naphthyl, or heterocyclic aromatic group, or may combine to form one or more aromatic rings. B1 and B2 may further include one or more substituents. R3, R4, R5, R6, and R16 are selected independently from the group consisting of hydrogen, halogen, —Ra, —OH, —ORa, —O—CO—Ra, —CN, —NO2, —SO2Ra, —SORa, —SH, —SRa, —NH2, —NHRa, —NRaRa, or —NRbRc; or wherein R5 and R6 combine to form a cyclic group. Ra may include an alkyl, polycycloalkyl, alkenyl, polyalkenyl, haloalkyl, perhaloalkyl, alkynyl, polyalkynyl, hydroxyalkynyl, polyhydroxyalkynyl; or (C3-20)cycloalkyl group. Rb and Rc may include hydrogen or alkyl groups, or may combine to form a saturated heterocyclic group, or together with an adjacent phenyl group may form a julolidinyl group. R7 is a mesogenic group.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Applicant: AlphaMicron Incorporated
    Inventors: Ludmila Sukhomlinova, Linli Su, Tamas Kosa, Bahman Taheri
  • Patent number: 8765719
    Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: July 1, 2014
    Assignee: Kagoshima University
    Inventors: Masanori Baba, Yuichi Hashimoto
  • Publication number: 20140154514
    Abstract: A photochromic compound is provided, which may be a pyran, an oxazine, or a fulgide. The photochromic compound has at least one substituent Q attached thereto, each Q independently being —N3, —CN, —COOR?, —CCR?, —C(R?)C(R?)R?, —OCOR?, —OCOOR?, —SR?, —OSO2R??, and/or —CON(R?)R?, wherein each R? is hydrogen, an unsubstituted or substituted alkyl group having from 1 to 18 carbon atoms; an unsubstituted or substituted aryl group, an unsubstituted or substituted alkene or alkyne group having from 2 to 18 carbon atoms, wherein the substituents are halo or hydroxyl and R?? is —CF3 or a perfluorinated alkyl group having from 2 to 18 carbon atoms. The number, locations and nature of the constituents Q are dependent upon the structure of the photochromic compound.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: TRANSITIONS OPTICAL, INC.
    Inventors: Meng He, Darrin R. Dabideen, Anil Kumar, Terry A. Keller, II
  • Patent number: 8703978
    Abstract: A naphthopyran compound represented by the formulae (I) to (II) wherein: —mi, Hi2, p, q are each an integer comprised from O to 4 or 5 inclusive; —Ri, R2 and R4, represent a group selected from halogen, H, —Ra, aryl, —OH, —ORa, —SH, —SRa, —NH2, —NR8RaI, —NRbRc, —NRal-CORa, —NRaiCO(aryl), —NRai aryl, —N-aryfe, —N(aryl)CO(aryl), —CO—R3, —CO2R3I, —OC(O)—Rd, and —X—(Re)—Y, and linear or branched (Ci-Ci8) perfluoroalkyl group, wherein R3, Rai, Rb, Rc, X, Y, Re, Rd are as defined into the description; —Zi re resent a group selected from: (formules).
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: April 22, 2014
    Assignee: Essilor International (Compagnie Generale d'Optique)
    Inventors: Stuart Aiken, Christopher David Gabbutt, Bernard Mark Heron, Christopher Stephen Kershaw, Nicola Jane Smith, Jean-Paul Cano
  • Patent number: 8705160
    Abstract: A photochromic compound is provided, which may be a pyran, an oxazine, or a fulgide. The photochromic compound has at least one substituent Q attached thereto, each Q independently being —N3, —CN, —COOR?, —CCR?, —C(R?)C(R?)R?, —OCOR?, —OCOOR?, —SR?, —OSO2R??, and/or —CON(R?)R?, wherein each R? is hydrogen, an unsubstituted or substituted alkyl group having from 1 to 18 carbon atoms; an unsubstituted or substituted aryl group, an unsubstituted or substituted alkene or alkyne group having from 2 to 18 carbon atoms, wherein the substituents are halo or hydroxyl and R?? is —CF3 or a perfluorinated alkyl group having from 2 to 18 carbon atoms. The number, locations and nature of the constituents Q are dependent upon the structure of the photochromic compound.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 22, 2014
    Assignee: Transitions Optical, Inc.
    Inventors: Meng He, Darrin R. Dabideen, Anil Kumar, Terry A. Kellar, II
  • Patent number: 8697890
    Abstract: A naphthopyran compound represented by the formula B1 and B2 are selected from a phenyl, naphthyl, or heterocyclic aromatic group, or may combine to form one or more aromatic rings. B1 and B2 are optionally substituted with one or more substituents. R3, R4, R5, R6, and R10 are selected independently from hydrogen, halogen, —Ra, —OH, —ORa, —O—CO—Ra, —CN, —NO2, —SO2Ra, —SORa, —SH, —SRa, —NH2, —NHRa, —NRaRa, and —NRbRc. Any two or more of R5, R6 or R10 may combine to form a cyclic group. R7 is a mesogenic group containing at least two rings connected to each other through a covalent bond or linking unit. The linking unit is an ester, —Rd—, —O—, —ORd—, —ORdO—, —OCORd—, —OCORdO—, —S—, —CH?CH—, —CH?N—, —C?C—, or —N?N—, where Rd is a linear or branched (C1-18)alkyl or a linear or branched (C1-18)haloalkyl group. The naphthopyran compound may be incorporated into an optical article.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: April 15, 2014
    Assignee: Alphamicron Incorporated
    Inventors: Ludmila Sukhomlinova, Linli Su, Tamas Kosa, Bahman Taheri
  • Publication number: 20140027684
    Abstract: A photochromic polymer comprising at least two photochromic moieties linked by a straight or branched chain polymer selected from the group consisting of a homo-polyester, a co-polyester, and a co-polyester-polyether.
    Type: Application
    Filed: May 21, 2012
    Publication date: January 30, 2014
    Applicant: VIVIMED LABS EUROPE LTD
    Inventors: Richard Alexander Evans, Nino Malic, Ian John Dagley
  • Patent number: 8608988
    Abstract: The present invention provides a curable, organic polymeric photochromic composition comprising: a photochromic amount of at least one photochromic material; a polymeric polyol having carbonate groups along its backbone and having a number average molecular weight greater than 5000 g/mole; and a curing agent having reactive functional groups capable of reacting with hydroxyl groups on the polymeric polyol. After curing and after the Photochromic Performance Test the composition demonstrates a T1/2 fade rate of less than 200 seconds. Also provided is a photochromic article comprising a rigid substrate and a photochromic organic polymeric coating applied to a surface of the substrate. The photochromic organic polymeric coating comprises the composition described above.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 17, 2013
    Assignee: Transitions Optical, Inc.
    Inventors: Steven E. Bowles, Cynthia Kutchko, Paul H. Lamers, Jason R. Lewis, David E. Sartori, Robert W. Walters, Feng Wang
  • Publication number: 20130302422
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 14, 2013
    Applicants: KT & G CORPORATION, MAZENCE INC.
    Inventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
  • Publication number: 20130303550
    Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.
    Type: Application
    Filed: November 11, 2011
    Publication date: November 14, 2013
    Applicants: Ruprecht-Karls-Universitat Heidelberg, Deutsches Krebsforschungszentrum
    Inventors: Michael Boutros, Rajendra-Prasad Maskey, Corinna Koch, Florian Fuchs, Sandra Steinbrink, Daniel Gilbert
  • Publication number: 20130296344
    Abstract: Compounds according to the general formula (I) wherein X1, X2, X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different, and wherein up to 3 of the group X1, X2, X3 and X4 may be N; A is a 5- or 6-membered aromatic or heteroaromtic cycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S wherein A may be substituted by 1 to 5 substituents R which may be same or different; their solvates, hydrates, and pharmaceutically acceptable salts for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal selected from a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis).
    Type: Application
    Filed: November 11, 2011
    Publication date: November 7, 2013
    Applicants: Ruprecht-Karls-Universitat Heidelberg, Deutsches Krebsforschungszentrum
    Inventors: Michael Boutros, Rajendra-Prasad Maskey, Corinna Koch, Florian Fuchs, Sandra Steinbrink, Daniel Gilbert
  • Patent number: 8500807
    Abstract: The invention relates to an intraocular lens comprising at least one pharmaceutically-acceptable photochromic polymer that enables all or part of the intraocular lens to change colour reversibly when exposed to light.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: August 6, 2013
    Assignee: Carl Zeiss Meditec SAS
    Inventors: Pascal Bernard, Marc Dolatkhani, Anne Pagnoux, Christophe Hupin
  • Publication number: 20130183388
    Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 18, 2013
    Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventor: Lankenau Institute for Medical Research
  • Patent number: 8486312
    Abstract: The present invention relates to photochromic naphthopyrancs having a double-bridged terphenyl sub-unit, and to the use thereof in plastics of all types, particularly for ophthalmic purposes.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: July 16, 2013
    Assignee: Rodenstock GmbH
    Inventors: Manfred Melzig, Yven Rohlfing, Udo Weigand
  • Patent number: 8389568
    Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: March 5, 2013
    Assignee: Lankenau Institute for Medical Research
    Inventors: George C. Prendergast, William P. Malachowski, Alexander J. Muller
  • Publication number: 20120289577
    Abstract: The present invention relates to a composition for treating or preventing hearing loss comprising naphthoquinone-based compounds.
    Type: Application
    Filed: December 27, 2010
    Publication date: November 15, 2012
    Applicant: KT&G LIFE SCIENCES CORPORATION
    Inventors: Tae Hwan Kwak, Myung-Gyu Park, Hong-Seob So, Raekil Park, Hyung-Jin Kim
  • Patent number: 8303844
    Abstract: The present invention relates to benzo[f]chromene and pyrano[3,2-f]-chromene derivatives of the formula I in which L1, L2, R1, R2, A1, A2, Z1, Z2, m and n are as defined in claim 1, to the preparation thereof, to the use thereof as components in liquid-crystalline media, and to electro-optical display elements which contain the liquid-crystalline media according to the invention.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: November 6, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Axel Jansen, Melanie Klasen-Memmer
  • Publication number: 20120200907
    Abstract: A photochromic compound is provided, which may be a pyran, an oxazine, or a fulgide. The photochromic compound has at least one substituent Q attached thereto, each Q independently being —N3, —CN, —COOR?, —CCR?, —C(R?)C(R?)R?, —OCOR?, —OCOOR?, —SR?, —OSO2R??, and/or —CON(R?)R?, wherein each R? is hydrogen, an unsubstituted or substituted alkyl group having from 1 to 18 carbon atoms; an unsubstituted or substituted aryl group, an unsubstituted or substituted alkene or alkyne group having from 2 to 18 carbon atoms, wherein the substituents are halo or hydroxyl and R?? is —CF3 or a perfluorinated alkyl group having from 2 to 18 carbon atoms. The number, locations and nature of the constituents Q are dependent upon the structure of the photochromic compound.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 9, 2012
    Applicant: TRANSITIONS OPTICAL, INC.
    Inventors: Meng He, Darrin R. Dabideen, Anil Kumar, Terry A. Kellar, II
  • Publication number: 20120184604
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases comprising colforsin daropate, and more particularly, the present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases such as bone fracture and osteoporosis, which inhibits osteoclast differentiation and bone resorption caused by osteoclasts and promotes osteoblast differentiation and the activity of osteoblasts, and a health functional food composition comprising colforsin daropate.
    Type: Application
    Filed: July 16, 2010
    Publication date: July 19, 2012
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Byoung Mog Kwon, Dong Cho Han, Myung Ae Bae, Seong Hwan Kim, Yong Ki Min
  • Patent number: 8211338
    Abstract: A photochromic compound is provided, which may be a pyran, an oxazine, or a fulgide. The photochromic compound has at least one substituent Q attached thereto, each Q independently being —N3, —CN, —COOR?, —CCR?, —C(R?)C(R?)R?, —OCOR?, —OCOOR?, —SR?, —OSO2R??, and/or —CON(R?)R?, wherein each R? is hydrogen, an unsubstituted or substituted alkyl group having from 1 to 18 carbon atoms; an unsubstituted or substituted aryl group, an unsubstituted or substituted alkene or alkyne group having from 2 to 18 carbon atoms, wherein the substituents are halo or hydroxyl and R?? is —CF3 or a perfluorinated alkyl group having from 2 to 18 carbon atoms The number, locations and nature of the constituents Q are dependent upon the structure of the photochromic compound.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: July 3, 2012
    Assignee: Transitions Optical, Inc
    Inventors: Meng He, Darrin R. Dabideen, Anil Kumar, Terry A. Kellar, II
  • Patent number: 8148551
    Abstract: The invention relates to tricyclic aromatics of the general formula I in which A1, A2, A3, A4, Q1-Q2, R1, R2, X1, X2, X3, Z1, Z2, Z3, Z4, q, r, s, t and u have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing same.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: April 3, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschraenkter Haftung
    Inventors: Rudolf Eidenschink, Holger Kretzschmann
  • Publication number: 20120022103
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Erol K. Bayburt, Jerome F. Daanen, Arthur R. Gomtsyan, Steven P. Latshaw, Chih-hung Lee, Robert G. Schmidt, JR.
  • Publication number: 20110251236
    Abstract: Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay.
    Type: Application
    Filed: August 14, 2008
    Publication date: October 13, 2011
    Applicant: University of Miami
    Inventors: Kent Lai, Klass Jan Wierenga, Manshu Tang
  • Publication number: 20110172185
    Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
    Type: Application
    Filed: August 22, 2009
    Publication date: July 14, 2011
    Inventors: Masanori Baba, Yuichi Hashimoto
  • Publication number: 20110122475
    Abstract: A naphthopyran compound represented by the formulae (I) to (II) wherein:—mi, Hi2, p, q are each an integer comprised from O to 4 or 5 inclusive;—Ri, R2 and R4, represent a group selected from halogen, H, —Ra, aryl, —OH, —ORa, —SH, —SRa, —NH2, —NR8RaI, —NRbRc, —NRaI-CORa, —NRaiCO(aryl), —NRai aryl, —N-aryfe, —N(aryl)CO(aryl), —CO—R3, —CO2R3I, —OC(O)—Rd, and —X—(Re)—Y, and linear or branched (Ci-Ci8) perfluoroalkyl group, wherein R3, RaI, Rb, Rc, X, Y, Re, Rd are as defined into the description;—Zi re resent a group selected from: (formules)
    Type: Application
    Filed: March 2, 2009
    Publication date: May 26, 2011
    Applicant: Essilor International (compagnie Generale D'optique)
    Inventors: Stuart Aiken, Christopher David Gabbutt, Bernard Mark Heron, Christopher Stephen Kershaw, Nicola Jane Smith, Jean-Paul Cano
  • Publication number: 20110117649
    Abstract: Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.
    Type: Application
    Filed: December 13, 2010
    Publication date: May 19, 2011
    Inventors: Karl Scheidt, Margaret Marie Biddle
  • Patent number: 7935822
    Abstract: The present invention relates to carboxamide-substituted dyes, the production and use of such dyes as labeling groups in analytics.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: May 3, 2011
    Assignee: ATTO-TEC GmbH
    Inventors: Jutta Arden-Jacob, Karl-Heinz Drexhage, Monika Hamers-Schneider, Norbert Kemnitzer, Alexander Zilles
  • Publication number: 20110092695
    Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 21, 2011
    Inventors: WenYong Chen, Ravi Bhatia, Leila Su, Yate-Ching Yuan
  • Publication number: 20110043746
    Abstract: The present invention relates to benzo[f]chromene and pyrano[3,2-f]-chromene derivatives of the formula I in which L1, L2, R1, R2, A1, A2, Z1, Z2, m and n are as defined in claim 1, to the preparation thereof, to the use thereof as components in liquid-crystalline media, and to electro-optical display elements which contain the liquid-crystalline media according to the invention.
    Type: Application
    Filed: November 3, 2008
    Publication date: February 24, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Axel Jansen, Melanie Klasen-Memmer
  • Publication number: 20110020448
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of glaucoma, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 27, 2011
    Applicants: MAZENCE, INC., KT & G CORPORATION
    Inventors: Myung-Gyu Park, Taehwan Kwak
  • Publication number: 20110002995
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 6, 2011
    Applicants: MAZENCE INC., KT & G CORPORATION
    Inventors: Taehwan Kwak, Myung-Gyu Park
  • Publication number: 20100324296
    Abstract: A naphthopyran compound represented by the formula B1 and B2 may include a phenyl, naphthyl, or heterocyclic aromatic group, or may combine to form one or more aromatic rings. B1 and B2 may further include one or more substituents. Ra may include an alkyl, polycycloalkyl, alkenyl, polyalkenyl, haloalkyl, perhaloalkyl, alkynyl, polyalkynyl, hydroxyalkynyl, polyhydroxyalkynyl; or (C3-20)cycloalkyl group. Rb and Rc may include hydrogen or alkyl groups, or may combine to form a saturated heterocyclic group, or together with an adjacent phenyl group may form a julolidinyl group. R3, R4, R5, R6, and R10 may include hydrogen, halogen, —Ra, —OH, —ORa, —O—CO—Ra, —CN, —NO2, —SO2Ra, —SORa, —SH, —SRa, —NH2, —NHRa, —NRaRa, or —NRbRc; or any two or more may combine to form a cyclic group. R7 is a mesogenic group. And the naphthopyran, which may be referred to as a dichroic-photochromic compound, may be incorporated into an optical article.
    Type: Application
    Filed: October 17, 2007
    Publication date: December 23, 2010
    Inventors: Ludmila Sukhomlinova, Linli Su, Tamas Kosa, Bahman Taheri
  • Patent number: 7851640
    Abstract: Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: December 14, 2010
    Assignee: Northwestern University
    Inventors: Karl Scheidt, Margaret Marie Biddle
  • Publication number: 20100310657
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: December 9, 2010
    Applicants: MAZENCE INC., KT & G CORPORATION
    Inventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
  • Patent number: 7842721
    Abstract: A pharmaceutical composition having a cytotoxic effect to a cancer cell is provided. The pharmaceutical composition includes a flavonoid compound having a formula as wherein B ring is a 4-oxo-cyclohexa-2,5-dienyl group, and any one of R1-R12 is one selected from a group consisting of hydrogen group, hydroxyl group, C1-C20 alkyl group, C1-C20 ether group, C1-C20 ester group, carboxyl group, halogen and sugar. The flavonoid compound is obtained from a chemical method being one of a total synthesis method and a semi-synthesis method.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: November 30, 2010
    Assignee: Kaohsiung Medical University
    Inventors: An-Shen Lin, Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang
  • Patent number: 7812051
    Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: October 12, 2010
    Assignee: ArQule, Inc.
    Inventors: Mark A. Ashwell, Chiang J. Li, Manish Tandon, Yanbin Liu, Jean-Marc LaPierre, Zhiwei Jiang
  • Publication number: 20100255054
    Abstract: Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
    Type: Application
    Filed: November 26, 2007
    Publication date: October 7, 2010
    Inventors: Taehwan Kwak, Sang-ku Yoo, Myung-gyu Park
  • Patent number: 7790765
    Abstract: The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: September 7, 2010
    Assignee: ArQule, Inc.
    Inventors: Judit Bartis, Erika Volckova, Manish Tandon, Deirdre Lowe, Martin P. Redmon
  • Publication number: 20100059711
    Abstract: The invention relates to fused naphthalenes of the general formula I, in which A1, A2, A3, A4, Q1-Q2, G1-G2, R1, R2, X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4, q, r, s and t have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing them.
    Type: Application
    Filed: July 4, 2007
    Publication date: March 11, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Holger Kretzschmann, Rudolf Eidenschink
  • Publication number: 20100039688
    Abstract: A naphthopyran compound represented by the formula (I) wherein: n1, n2, p, m and q represent an integer; R1, R2 and R4, represent a group selected from halogen, —Ra, —OH, —ORa, —SH, —SRa, —NH2, —NRaRa1, —NRbRc, —CO—Ra, —CO2Ra1, —OC(O)—Rd, —X—(Re)—Y, linear or branched (C1-C18) perfluoroalkyl group, wherein Ra, Ra1, Rb, Rc, X, Y, Re, and Rd are as defined in the description; Z represents a group selected from CO, CS, SO, SO2, CO2, C(O)S, CS2, C(O)NH, C(O)NRa, C(S)NH, C(S)NRa and C?NRa; R3 represents a group selected from halogen, —Ra, linear or branched (C1-18) perfluoroalkyl group —OH, —ORa, —SH, —SRa, —NH2, and —NRaRa1; R6 represents a group selected from —Ra which may be optionally substituted, linear or branched (C1-18) perfluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, which may be optionally substituted; R5 represents a group selected from: halogen, —Ra, linear or branched (C1-18) perfluoroalkyl group, —OH, —ORa, —SH, —SRa, —NH2, —NRaRa1, —CO—Ra, —O—C(O)—Ra and —CO2Ra1; or when q is equa
    Type: Application
    Filed: September 5, 2007
    Publication date: February 18, 2010
    Inventors: Stuart Aiken, Jean-Paul Cano, Christopher David Gabbutt, Bernard Mark Heron
  • Patent number: 7638554
    Abstract: Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) wherein R1 through R3 and R5 through R11 are defined herein, and ?, ? and ? are optional bonds, providing that when ? is absent, ? is present, and when ? is absent, ? is present. When ? is present, preferred R4 moieties are selected from O, S, NH and CH2, and when ? is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When ? is present, the preferred R5 substituent is O, while when ? is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: December 29, 2009
    Assignee: SRI International
    Inventors: Nahid Waleh, Nurulain T. Zaveri
  • Publication number: 20090309076
    Abstract: A photochromic compound is provided, which may be a pyran, an oxazine, or a fulgide. The photochromic compound has at least one substituent Q attached thereto, each Q independently being —N3, —CN, —COOR?, —CCR?, —C(R?)C(R?)R?, —OCOR?, —OCOOR?, —SR?, —OSO2R??, and/or —CON(R?)R?, wherein each R? is hydrogen, an unsubstituted or substituted alkyl group having from 1 to 18 carbon atoms; an unsubstituted or substituted aryl group, an unsubstituted or substituted alkene or alkyne group having from 2 to 18 carbon atoms, wherein the substituents are halo or hydroxyl and R?? is —CF3 or a perfluorinated alkyl group having from 2 to 18 carbon atoms The number, locations and nature of the constituents Q are dependent upon the structure of the photochromic compound.
    Type: Application
    Filed: December 5, 2008
    Publication date: December 17, 2009
    Applicant: TRANSITIONS OPTICAL, INC.
    Inventors: Meng He, Darrin R. Dabideen, Anil Kumar, Terry A. Kellar, II
  • Patent number: 7584630
    Abstract: Described are photochromic ocular devices such as contact lenses and intraocular lenses made of an organic polymeric material and at least one photochromic material capable upon exposure to actinic radiation to change from a less ultraviolet radiation absorbing unactivated form to a more ultraviolet radiation absorbing activated form. The photochromic ocular device is capable upon exposure to actinic radiation to exhibit a ratio of greater than 0.5:1.0 of increased ultraviolet radiation absorbance to increased visible radiation absorbance as measured in the Ultraviolet Photochromic Performance Test described herein.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: September 8, 2009
    Assignee: Transitions Optical, Inc.
    Inventor: Barry Van Gemert
  • Publication number: 20090170926
    Abstract: The present invention provides a method of treatment or prophylaxis of hepatitis B virus in a subject comprising administering an effective amount of a compound of formula (1) or a pharmaceutically acceptable derivative, salt or prodrug thereof. In addition, there is provided compounds of formula (1) and pharmaceutical compositions thereof. Further, methods of preparing compounds of formula (1) are disclosed.
    Type: Application
    Filed: March 31, 2005
    Publication date: July 2, 2009
    Applicant: Monash Univeristy
    Inventors: Jonathan Alan Victor Coates, Eric Dale Jones, Susan Cox, Ian Crosby, David Gerard Bourke, Tyrone Pieter Jeynes
  • Publication number: 20090131689
    Abstract: The invention relates to tricyclic aromatics of the general formula I in which A1, A2, A3, A4, Q1-Q2, R1, R2, X1, X2, X3, Z1, Z2, Z3, Z4, q, r, s, t and u have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing same.
    Type: Application
    Filed: December 29, 2006
    Publication date: May 21, 2009
    Inventors: Rudolf Eidenschink, Holger Kretzschmann
  • Publication number: 20090054516
    Abstract: A pharmaceutical composition having a cytotoxic effect to a cancer cell and a method for the same are provided. The pharmaceutical composition comprises a flavonoid compound having at least one of the following formulas: wherein B ring is a 4-oxo-cyclohexa-2,5-dienyl group, and any one of R1-R12 is one selected from a group consisting of hydrogen group, hydroxyl group, C1-C20 alkyl group, C1-C20 ether group, C1-C20 ester group, carboxyl group, halogen and sugar.
    Type: Application
    Filed: August 24, 2007
    Publication date: February 26, 2009
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yang-Chang Wu, An-Shen Lin, Kuo-Hsiung Lee, Fang-Rong Chang